And Then There Were 12: Follow-on Biologics Picture Coming Into Focus
Executive Summary
It almost seems like the conference committee negotiations for follow-on biologics legislation have begun, but the two actors that the generic industry expects to best represent its issues - Rep. Henry Waxman, D-Calif., and President Obama - are not at the table
You may also be interested in...
Recapping The HELP Health Reform Bill, Passed By Committee July 15
The Senate Health, Education Labor and Pensions Committee's health reform bill was the first major piece of health care reform legislation to emerge from the committee stage when it was approved by the HELP panel July 15 in a party-line 13-10 vote. No Republicans on the committee supported the bill
Recapping The HELP Health Reform Bill, Passed By Committee July 15
The Senate Health, Education Labor and Pensions Committee's health reform bill was the first major piece of health care reform legislation to emerge from the committee stage when it was approved by the HELP panel July 15 in a party-line 13-10 vote. No Republicans on the committee supported the bill
Follow-on Biologics Showdown In House Set For July 17
House tri-committee bill is silent on follow-on biologics, but Rep. Anna Eshoo wants to be heard. Can the germaneness rule save Rep. Waxman from defeat?